Tumour-agnostic drugs ‘game-changing’, says NICE as it rejects one from Bayer
Bayer, Oncology, rare cancer, Roche, Rozlytrek, Vitrakvi
0 Comment
rare cancer
Daiichi Sankyo’s pexidartinib is first FDA-approved drug for rare tumour
Daiichi Sankyo, FDA approval, rare cancer, rare disease
0 Comment
NICE recommends Pfizer’s Xalkori in rare lung cancer
lung cancer, NSCLC, Pfizer, rare cancer, rare disease, Xalkori
0 Comment
NICE has issued a Final Appraisal Determination that recommends the use of Pfizer’s Xalkori (crizotinib) in England under the Cancer Drugs Fund (CDF) for patients with ROS1-positive advanced non-small cell lung cancer (NSCLC).
Immunocore’s rare cancer treatment gains UK Promising Medicine designation
cancer, Immunocore, innovative medicine, Oncology, Promising Innovative Medicine, rare cancer
0 Comment
Immunocore has gained a Promising Innovative Medicines (PIM) designation in the UK for its candidate immunotherapy for patients with metastatic uveal melanoma, a rare tumour of the eye.